Tuesday, May 29, 2018
Boston Scientific Europe today announced the launch of HeartLogic ™ for the diagnosis of heart failure in Europe. With the launch, the first and only diagnostic tool that allows preventive care of heart failure (HF) is available in several select countries in Europe including Italy, Spain, the United Kingdom, Germany, Austria and Switzerland, with more countries coming soon.
Currently, heart failure affects more than 15 million people in Europe and accounts for approximately 3 million hospitalizations and multiple deaths per year [1] . The HeartLogic diagnosis provides continuous measurements of early indications of worsening heart failure by combining data from sensors that assess heart sounds, respiratory rate and volume, chest impedance, frequency and cardiac activity. The unique algorithm of HeartLogic is integrated in Resonate ™ and defibrillators for cardiac resynchronization therapy (CRT-D) and internal cardiac defibrillators (ICD) of the next generation.
"Today, heart failure is the leading cause of hospitalization in people over 65 years of age and poses a tremendous economic burden on health care systems, and after initial hospitalization, 24 percent of patients with heart failure return. to be hospitalized within a 30-day period. [2], [3], [4] With HeartLogic, physicians will be able to predict events of heart failure weeks before they happen, can intervene early and help reduce hospitalization of patients , "commented university professor John Morgan , head of medical operations and medical director of rhythm management at Boston Scientific in Europe.
The multi-sensor chronic evaluation study in ambulatory patients with heart failure (MultiSENSE) evaluated the performance of HeartLogic ™ Diagnostic to predict impending decompensation of heart failure (HF). In the MultiSENSE study, HeartLogic successfully detected 70% of heart failure events in advance, notifying physicians several weeks in advance in most cases [5] .
"Doctors can detect early warning signs of a worsening of heart failure symptoms with HeartLogic for diagnosis of heart failure, which gives them valuable time to address the different pathophysiological aspects of heart failure, adjust treatment, avoid potential readmissions to the hospital and, ultimately, improve the care and overall outcome of the patient, "said John P. Boehmer , MD, principal investigator and director of the heart failure program at Penn State Health Medical Center Milton S. Hershey and professor of medicine at Penn State College of Medicine .
Several new analyzes of the MultiSENSE study were presented at the Heart Failure congress that was held in Vienna from May 26 to 29. The data revealed that HeartLogic can detect changes in rapid shallow breathing patterns and thus enable better outcomes for patients with HF:
• Changes in the Rapid Shallow Breathing Index (RSBI) were correlated with changes in patients' dyspnea. For example, the increase in shallow breathing resulted in a worsening of dyspnea while mechanical ventilation (MV), a common marker that rises in patients with HF, did not have that result [6] .
• The RSBI that measured the device appeared significantly elevated in the three days before an HF event, while MV did not show significant differences [7] .
• The probability of hospital readmission or death increased when the RSBI that measured the device worsened during hospitalization after heart failure [8] .
Further:
• HeartLogic has had solid results in several patient demographics. The algorithm works effectively between various types of patients' bodies and for patients of different ethnicities.
• The analysis of heart sounds during the evaluation of ECHO in patients with atrial fibrillation (AF) confirmed the presence of a third heart sound (S3). An objective measure based on devices could provide a more consistent evaluation of S3 than auscultation during the arrhythmic rumble of AF.
Heart failure is a chronic, progressive disease in which the heart muscle can not pump enough blood to the cells of the body. This can result in symptoms such as fatigue, respiratory problems and cough: the management of HF can lead to multiple hospitalizations, which can have a detrimental effect on the outcome and the quality of life of the patient. Almost half of patients (46%) are re-hospitalized at 60 days after heart failure [7] .
